Portola Pharma (PTLA) Announces Plans to Present Interim Phase 3b/4 ANNEXA-4 Data
Tweet Send to a Friend
Portola Pharmaceuticals Inc. (Nasdaq: PTLA) announced that interim results from its ongoing Phase 3b/4 ANNEXA-4 trial of AndexXa (andexanet alfa) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
